I. The Patient Journey
At the time of primary diagnosis, what was most important to the patient when making choices about their care?
PATIENT VOICE
“As a scientist I have been involved in clinical research in the past and am aware of the impact clinical patient data can have, not only on drug development, but also on patient care and support. This is particularly relevant for ocular melanoma patients where the potential of metastases is real and ever present. The more data there is, the more valuable the analytics will be. Personally I have found VISION very interesting and informative, and particularly reassuring that I am not alone on this OM journey. By participating in VISION, I have been able to make my small contribution to
% of patients ranking 1st, 2nd or 3rd 78%
% of patients ranking 1st
Most important issues
Most important issues
46%
Long-term survival
Long-term survival
31%
65%
Experience of the medical team in OM
Experience of the medical team in OM
5%
23%
Impact on family
Overall quality of life
Does not preclude future treatment options
5%
22%
Ability to obtain care closer to home
the wider OM community.” — VISION Participant in Ireland
1%
21%
Overall quality of life
Impact on family
1%
15%
Expenses for care
Expenses for care
0% 1% 0%
12%
Ability to obtain care closer to home
Insurance coverage
Does not preclude future treatment options
10%
Insurance coverage
1%
Support services offered
Support services offered
2023 VISION Registry Data Report
26
Made with FlippingBook Ebook Creator